Clinical trials: IBS, Constipation Predominant
Constipation Predominant Irritable Bowel Syndrome
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as…
- Trial name
- T3MPO-2 (NCT02686138)
- Testing
- Tenapanor
- Where
- 117 sites in United States
- Volunteers
- 593 people
- Sponsor
- Ardelyx
Constipation-predominant Irritable Bowel Syndrome
Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype
The main objective is to assess the effect of an 8-week daily supplementation with IbSium® (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal disorders associated to the type C IBS…
- Trial name
- IBS-GO (NCT03150212)
- Testing
- Saccharomyces cerevisiae CNCM I-3856
- Where
- 5 sites in France
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Lesaffre International
IBS, Diarrhea Predominant, IBS, Constipation Predominant
Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot
Purpose: The associations between pain, stress, bloating, and their short interval temporal relationships to defecation in IBS D, C \& M are of great interest to the field of functional GI disorders, but have not been adequately…
- Conditions
- IBS, Diarrhea Predominant, IBS, Constipation Predominant, IBS, Mixed Symptoms
- Trial name
- NCT00619125
- Testing
- palm pilot recording responses to questionnaires
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C)
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Goal of this study is to evaluate the efficacy and safety of two different doses of Linaclotide in improving bowel function and patient-reported outcomes among Bangladeshi patients with chronic constipation for 8 weeks along with…
- Conditions
- Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C), Chronic Constipation, CIC
- Trial name
- LIN-CC-BD (NCT07431957)
- Testing
- Linaclotide 72 micrograms, Linaclotide 145 micrograms
- Where
- Bangladesh
- Volunteers
- 90 people
- Sponsor
- Md Mehedi Shahriar
Constipation - Functional, Abdominal Pain (AP)
Co-Development and Validation of Colonic Symptom Pictograms for Young People
Severe constipation affects 10% of children, often leading to significant physical and emotional distress. While constipation is commonly associated with impaired bowel movements, it is fundamentally linked to abnormalities in…
- Conditions
- Constipation - Functional, Abdominal Pain (AP), Nausea and Vomitting, Bloating
- Trial name
- NCT07337343
- Testing
- Pictogram comprehension and validation
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Auckland, New Zealand
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome Characterized by Constipation
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).
- Trial name
- NCT03923322
- Testing
- Botanical Tincture
- Where
- United States
- Sponsor
- Stamford Hospital
Constipation-predominant IBS (IBS-C)
Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)
The objective of this Phase II trial is to test the NTX-1 Fiber in patients with constipation-predominant IBS (IBS-C) and determine if it can reduce symptoms, beneficially modify gut microbiota composition, and improve gut milieu…
- Trial name
- NCT02144753
- Testing
- NTX-1, psyllium (15 g)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Nutrabiotix, LLC
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Constipation-predominant Irritable Bowel Syndrome (IBS-C)
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
This study is to investigate the efficacy, safety, and plasma concentration change of ASP0456 in patients with constipation-predominant irritable bowel syndrome.
- Trial name
- NCT01714843
- Testing
- linaclotide
- Where
- 4 sites in Japan
- Volunteers
- 559 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the Western world, seen predominantly in females and with a negative impact on quality of…
- Trial name
- NCT00220090
- Testing
- dexloxiglumide
- Where
- United Kingdom
- Sponsor
- Rottapharm
Bowel Symptoms, Depression Disorders
The Effect of Inulin in Irritable Bowel Syndrome
Purpose: This study was conducted to evaluate the effect of inulin on bowel symptoms, depression and quality of life in individuals with constipation-dominant irritable bowel syndrome.
- Conditions
- Bowel Symptoms, Depression Disorders, Inulin, Constipation
- Trial name
- NCT06610188
- Testing
- Prebiotic group
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mardin Artuklu University